ClinicalTrials.gg
RecruitingNCT06243575Updated Nov 21, 2024

Comparison of Outcomes Between Intraosseous Femoral and Tibial Injection in Simultaneous Bilateral Total Knee Arthroplasty Patients

An interventional study of Multimodal Intraosseous Femoral Injection and Multimodal Intraosseous Tibial Injection in Pain, Postoperative, sponsored by Department of Medical Services Ministry of Public Health of Thailand. Recruiting at 1 site in Thailand. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Department of Medical Services Ministry of Public Health of Thailand · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Pain, Postoperative with a site in Thailand — 5 open to participants now, 9 under way, 1 of them phase 3. Pain, Postoperative · Thailand.

Planned enrollment
61st of 63
20 · median 80
Started
2024
with 4 others
No phase
32 of 69
3 open now
Registered
58th of 69
by date
Lead sponsor
4 of 69
Department of Medical Services Ministry of Public Health of Thailand

Among the 69 studies in Pain, Postoperative with a site in Thailand, this one is the 61st largest by planned enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2024, is one of 32 with no phase, and was the 58th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

5 of the 69 studies in Pain, Postoperative with a site in Thailand are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Pain, Postoperative with a site in Thailand, or all of them as a file.
02

Study summary

In patients with osteoarthritis of the knee whose pain cannot be relieved by conservative treatment, total knee arthroplasty (TKA) is the operation that increases the quality of life for the patient. Pain management after total knee arthroplasty TKA is an important consideration to improve patient outcomes and reduce length of stay. Periarticular injections of the knee are one of the techniques used to reduce pain after surgery. Studies have shown that compared to other methods of pain relief, they are effective and safe. At present, no studies to compare between multimodal intraosseous femoral injection \& multimodal intraosseous tibial injection in Simultaneous Bilateral TKA patients.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • total knee arthroplasty
  • intraosseous infiltration
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who will undergo bilateral Total knee Replacement due to osteoarthritis of both knees
  • Used of a cemented, PS design TKA surgery.
  • Able to give

Exclusion criteria

Exclusion Criteria:

  • Revision TKA
  • History of previous knee or hip surgery
  • History of allergic reaction or side effects to the drug that will be used in the experiment
  • Underlying diseases of chronic kidney disease or chronic liver disease ( B or C)
  • Pregnancy
  • History of coagulopathy or abnormal blood coagulation profile( >1.4 or aPTT ratio > 1.4)
  • History of dysfunction or platelet count \< 140,0000/mm3
  • History of Thromboembolism
  • Use of Anticoagulants.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Multimodal Intraosseous Femoral Injection

    Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in femoral canal

    Drug: Multimodal Intraosseous Femoral Injection

  • Experimental
    Multimodal Intraosseous Tibial Injection

    Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in tibial canal

    Drug: Multimodal Intraosseous Tibial Injection

Interventions

  • DrugMultimodal Intraosseous Femoral Injection

    Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in femoral canal

  • DrugMultimodal Intraosseous Tibial Injection

    Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in tibial canal

06

What researchers measure

Primary outcomes

  1. Pain score (Visual analog scale)

    Visual analog scale (VAS) score from 0-10(0 was no pain, 10 was worst pain ) between multimodal intraosseous femoral injection \& multimodal intraosseous tibial injection

    Time frame: at 12 hours, 24 hours, 48 hours and 2 weeks after surgery

Secondary outcomes

  1. Amount of painkillers used

    Time frame: up to 24 hours after surgery

  2. Post operative blood loss

    Time frame: intraoperative and up to 48 hours postoperatively (include intraoperative and drain)

  3. Knee and Osteoarthritis Outcome Score (KOOS)

    minimum and maximum values(0-100), higher scores mean a better outcome.

    Time frame: post operative 2 weeks

  4. knee range of motion

    Time frame: post operative 2 weeks

  5. Side effects and complications

    Time frame: intraoperative to post operative 2weeks

  6. Length of hospital stay

    Length of hospital stay record in number of days

    Time frame: Admit to discharge date (up to 7 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Brozovich AA, Incavo SJ, Lambert BS, Sullivan TC, Wininger AE, Clyburn TA, Taraballi F, Park KJ. Intraosseous Morphine Decreases Postoperative Pain and Pain Medication Use in Total Knee Arthroplasty: A Double-Blind, Randomized Controlled Trial. J Arthroplasty. 2022 Jun;37(6S):S139-S146. doi: 10.1016/j.arth.2021.10.009. Epub 2022 Mar 7. PubMed 35272897 ↗
  • Fan L, Zhu C, Zan P, Yu X, Liu J, Sun Q, Li G. The Comparison of Local Infiltration Analgesia with Peripheral Nerve Block following Total Knee Arthroplasty (TKA): A Systematic Review with Meta-Analysis. J Arthroplasty. 2015 Sep;30(9):1664-71. doi: 10.1016/j.arth.2015.04.006. Epub 2015 Apr 8. PubMed 25922311 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Mar 2024, 1 month.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 1 month is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2024
First posted
Feb 6, 2024
StartActual
Feb 1, 2024
Primary completionActual
Mar 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06243575
Lead sponsor
Department of Medical Services Ministry of Public Health of Thailand
Responsible party
Sponsor
First posted
Feb 6, 2024
Start date
Feb 1, 2024
Primary completion
Mar 30, 2024
Completion
Dec 31, 2024 (estimated)
Last update
Nov 21, 2024

Study contacts

Thakrit Chompoosang, MD
Contact
tk_ortho@hotmail.com
+66846461916
Tanahem Wijit, MD
Contact
troy.erdos@gmail.com
+66956855458
Thakrit Chompoosang, MD
study director · Department of Medical Services Ministry of Public Health of Thailand

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion